July 1994
Mayo Clinic Health Letter;Jul1994, Vol. 12 Issue 7, p6
Presents an interview with Mayo Clinic psychiatrist Jeffrey D. Rome on antidepressants and mood-altering drugs. Ethical questions in their use; Selective serotonin re-uptake inhibitors; Prozac.


Related Articles

  • Nortriptyline superior to fluoxetine in first comparative trial for post-stroke depression.  // Formulary;May2000, Vol. 35 Issue 5, p453 

    Reports that tricyclic antidepressant nortriptyline appears to be superior to the selective serotonin reuptake inhibitor fluoxetine for treating post-stroke depression, according to Iowa researchers. Clinical tests results; Hamilton Rating Scale for Depression; Improvement in activities of...

  • Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Dekeyne, Anne; Iob, Loretta; Millan, Mark J. // Psychopharmacology;2001, Vol. 153 Issue 3, p389 

    Abstract Rationale: The discriminative stimulus (DS) properties of the selective serotonin (5-HT) uptake inhibitor (SSRI), citalopram, are mediated by 5-HT[sub 2C] receptors. Interestingly, the "atypical" antidepressants, mianserin and mirtazapine, behave as antagonists' at 5-HT[sub 2C]...

  • Sildenafil in the Treatment of Sexual Dysfunction Induced by Selective Serotonin Reuptake Inhibitors: An Overview. Nurnberg, H.G.; Hensley, P.L.; Lauriello, J. // CNS Drugs;2000, Vol. 13 Issue 5, p321 

    This review discusses the potential role of sildenafil in managing antidepressant-induced sexual dysfunction, with a focus on that associated with selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs). To provide a context, the epidemiology, assessment, prevalence with...

  • Evaluation of antidepressant-like activity of glycyrrhizin in mice. Dhingra, Dinesh; Sharma, Amandeep // Indian Journal of Pharmacology;Dec2005, Vol. 37 Issue 6, p390 

    Objective: To investigate the antidepressant-like effect of glycyrrhizin (glycyrrhizic acid ammonium) in mice. Materials and Methods: Glycyrrhizin (1.5, 3.0 and 6.0 mg/kg, i.p.) was administered once daily for seven successive days to separate groups of young male Swiss albino mice. The...

  • INTERACTION BETWEEN DESMETHYLIMIPRAMINE (DMI) AND RESERPINE ON SYMPATHETIC RESPONSES. Glover, Alice B.; McCulloch, Marian W. // Australian Journal of Experimental Biology & Medical Science;Aug1969, Vol. 47 Issue 4, pP13 

    Studies the interaction between desmethylimipramine (DMI) and reserpine on sympathetic responses. Role of antidepressant drugs in preventing or reversing the sedative and hypothermic effects of reserpine; Function of reserpine by depleting noradrenaline; Contribution of DMI in increasing the...

  • A South African herb that may rival Prozac. Carey, Sean // African Business;Mar2011, Issue 373, p52 

    The article reports that Zembrin, a patented extract of the herb Sceletium tortuosum, may replace antidepressants like Prozac and other selective serotonin reactive inhibitors (SSRIs). Zembrin is used as an analgesic, antispasmodic, sedative, tonic and mood elevator by the San and Khoi people of...

  • clomipramine:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p55 

    The article presents a definition of the term "clomipramine." Clomipramine, which is readily absorbed from the gastrointestinal tract and demethylated in the liver from the primary active metabolite desmethylclomipramime, refers to a tricyclic antidepressant that selectively inhibits the uptake...

  • Too soon to judge value of pharmacogenetic testing in selecting antidepressant. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;3/1/2007, Vol. 64 Issue 5, p453 

    The article presents information on the evaluation of pharmacogenetic testing in selecting antidepressant. A research was conducted on the testing for gene-based variations in the metabolism of selective serotonin-reuptake inhibitors under a project related to the evaluation of genomic...

  • Depression, a new hope.  // New Scientist;7/27/2013, Vol. 219 Issue 2927, p5 

    The article introduces a report within the issue on treatment alternatives for mental depression patients for whom serotonin-regulating drugs such as Prozac are ineffective.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics